Akums Drugs & Pharmaceuticals Ltd reported a b financial performance for the third quarter of the financial year 2025-26 (Q3 FY26), driven by growth in revenue and profitability.
For the quarter ended 31 December 2025, the company’s total revenue increased 14.8 percent year-on-year to Rs 1,160 crore, compared with Rs 1,010 crore in the corresponding quarter of the previous financial year.
Adjusted EBITDA rose 21 percent to Rs 147 crore during the quarter. Adjusted profit after tax (PAT) increased 29.5 percent to Rs 86 crore. Total EBITDA recorded a 1 percent increase to Rs 370 crore.
The company’s core contract development and manufacturing organisation (CDMO) segment reported revenue growth of more than 16 percent in the third quarter, supported by double-digit volume growth. The international branded formulations segment also recorded improvement, registering more than double the growth compared with the previous quarter due to increased demand in key global markets.
During Q3 FY26, the company strengthened its manufacturing network in line with international standards. Two production units received European Union Good Manufacturing Practice (EU GMP) certification.
The oral solids plant received renewal of EU GMP approval, while the oral liquids plant secured new EU GMP approval.
The company also received approval for the first time from the United Kingdom regulatory authority for the manufacturing of Rivaroxaban tablets.
